INTRODUCTION AND OBJECTIVES: Male circumcision (MC)
reduces the risk of HIV and other STIs. ShangRing (SR) obtained WHO-prequalification in 2015. Previous studies have indicated that SR MC provides a safe, simple, quick, and minimally invasive approach to MC. In this study, we evaluated an innovative no-flip SR technique which is purported to be faster, simpler, and equally safe in comparison with the standard SR technique.
METHODS: The no-flip technique involves inserting the inner ring of the SR under the foreskin followed by securely clamping the outer ring, providing hemostatic occlusion. The foreskin distal to the device is then excised. In this two-center RCT, the SR device was either removed at a 7-day follow-up or allowed to spontaneously detach. Each group was further divided into two sub-groups; 10-15 years and >15 years of age. Data on pain scores, adverse events (AEs), time to complete wound healing, and overall participant experience were collected.
RESULTS: Of the 230 participants circumcised at the two study sites, 114 were allocated to the 7-day removal group, and 116 to the spontaneous detachment group. All participants were eligible for SR MC without the limitation of phimosis and adhesions. Pain 20 minutes postoperatively was similar in both groups (median score of 3). 8.4% of participants from ring removal group required additional analgesia at the time of ring removal vs. 2.8% in spontaneous group during the postoperative period (p¼0.08). 27.6% of participants in the spontaneous detachment group requested device removal due to pain or discomfort. No AEs were severe. Moderate AEs were noted in 5.3% in the ring removal group vs. 1.7% in the spontaneous detachment group (p¼0.14). Wound healing on day-42 was comparable, 90% of participants in the spontaneous detachment group showed healing vs. 78% of ring removal participants (p¼0.57) (Figure 1 ). 97.7% of all participants were satisfied with the healed cosmetic appearance, and 99.5% were willing to recommend SR MC to others.
CONCLUSIONS: The no-flip SR technique was safe and effective; spontaneous detachment was generally acceptable to participants, allowing for comparable pain scores, wound healing, AE rates as well as equivalent safety compared to planned ring removal. METHODS: PCa patients with rising prostate specific antigen (PSA) who received 1 year continuous luteinizing hormone releasing hormone (LHRH) antagonist or agonist ADT, from two large, prospective, randomized, parallel arm, phase 3 trials (NCT00295750 and NCT00928434), with 1 year follow up, were pooled for analysis, comparing low (250ng/dL) vs. normal (250ng/dL) s-T level groups, and lowest vs. highest quartiles. Kaplan-Meier (K-M) survival estimates and Cox proportional hazards regression models were used to evaluate time to PSA rise, progression-free survival (PFS), and overall survival (OS).
RESULTS: 838 men (median age 72 years) were eligible for inclusion on an intention to treat analysis basis. 138 (16.5%) had baseline s-T 250ng/dL, and lower s-T quartile (n¼206) was 282ng/ dL vs. 503ng/dL for highest quartile (n¼210). s-T groups 250 vs. 250ng/dL respectively had comparable Gleason Grade 7-10 (55 vs. 58%), PSA 20ng/ml (38% each), locally advanced (15 vs. 24%) and metastatic stage (35 vs. 38%), with 30 vs. 32% unclassified stage at enrollment. Both analyses showed significantly worse survival endpoints (p0.05) for low baseline s-T PCa patients, except time to PSA progression (K-M plots below), with PFS and OS hazard ratios 1.86 and 4.85 respectively.
CONCLUSIONS: According to this analysis, biochemically hypogonadal, advanced PCa patients were disadvantaged by significantly worse 1-year progression-free and overall survival after continuous LHRH based medical castration. This new evidence should prompt International guidelines to recommend incorporating baseline s-T measurement in all hormone-naïve advanced PCa patients, to e712 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 
